Back to Journals » Drug Design, Development and Therapy » Volume 7

Management of difficult-to-treat patients with ulcerative colitis: focus on adalimumab

Authors Armuzzi A, Pugliese D, Nardone OM, Guidi L

Received 30 January 2013

Accepted for publication 13 March 2013

Published 8 April 2013 Volume 2013:7 Pages 289—296

DOI https://doi.org/10.2147/DDDT.S33197

Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 3


Alessandro Armuzzi, Daniela Pugliese, Olga Maria Nardone, Luisa Guidi

IBD Unit, Complesso Integrato Columbus, Catholic University, Rome, Italy

Abstract: The treatment of ulcerative colitis has changed over the last decade, with the introduction of biological drugs. This article reviews the currently available therapies for ulcerative colitis and the specific use of these therapies in the management of patients in different settings, particularly the difficult-to-treat patients. The focus of this review is on adalimumab, which has recently obtained approval by the European Medicines Agency and the US Food and Drug Administration, for use in treating adult patients with moderate-to-severe, active ulcerative colitis, who are refractory, intolerant, or who have contraindications to conventional therapy, including corticosteroids and thiopurines. Since the results emerging from the pivotal trials have been subject to some debate, the aim of this review was to summarize all available data on the use of adalimumab in ulcerative colitis, focusing also on a retrospective series of real-life experiences. Taken together, the current evidence indicates that adalimumab is effective for the treatment of patients with different types of ulcerative colitis, including biologically naïve and difficult-to-treat patients.

Keywords: randomized controlled trials, real-life experiences

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]